# Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ASD141

> **NCT06235437** · PHASE1 · RECRUITING · sponsor: **Ascendo Biotechnology Co., Ltd.** · enrollment: 21 (estimated)

## Conditions studied

- Metastatic Solid Tumor

## Interventions

- **BIOLOGICAL:** ASD141

## Key facts

- **NCT ID:** NCT06235437
- **Lead sponsor:** Ascendo Biotechnology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-29
- **Primary completion:** 2026-12
- **Final completion:** 2027-12
- **Target enrollment:** 21 (ESTIMATED)
- **Last updated:** 2026-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06235437

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06235437, "Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ASD141". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06235437. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*